The study followed more than 73,000 veterans receiving care through the U.S. Department of Veterans Affairs, one of the largest integrated health systems in the country. Researchers from UCSF, the San Francisco VA, VA Boston Healthcare System, Harvard Medical School, and Boston University School of Medicine analyzed treatment patterns over nearly two decades. Their work was conducted through PROFOUND-VET, a Veterans Affairs research initiative designed to develop and evaluate cancer-care guidelines. Rather than asking whether one individual treatment was superior in a randomized clinical trial, the investigators examined how real-world clinical practice changed across the VA system. The results reveal a striking transformation: a diagnosis that once commonly triggered immediate intervention is increasingly being managed through careful observation, repeated testing, and treatment only when biological evidence suggests that the cancer is becoming more dangerous.

Active surveillance is not the same as ignoring cancer. It is a structured monitoring program intended to separate tumors that remain biologically indolent from those that show signs of progression. Patients commonly undergo prostate-specific antigen, or PSA, blood testing every three to six months. PSA is a protein produced by prostate tissue, and changes in its concentration can provide clues about tumor activity, although the marker is not perfectly specific for cancer. Physicians may also perform digital rectal examinations, magnetic resonance imaging, and repeat prostate biopsies at longer intervals. MRI can reveal changes in the size, shape, or cellular characteristics of a suspicious lesion, while biopsy allows pathologists to reassess the tumor’s microscopic grade. If tests show that the cancer has grown, become more aggressive, or acquired other warning signs, the patient can move to definitive treatment with surgery or radiation.

The biological logic behind surveillance is rooted in the diversity of prostate tumors. Some prostate cancers grow slowly for many years, remain confined to the gland, and never cause symptoms or shorten a person’s life. Others are aggressive from the outset and can invade nearby tissues or spread to distant organs. Conventional screening can detect both types, but a positive diagnosis does not automatically reveal which biological path a tumor will follow. Treating every detected tumor as an immediate threat can therefore expose patients to the harms of therapy without providing a meaningful survival benefit. Prostate surgery may damage nerves and muscles involved in erections and urinary control, while radiation can contribute to urinary, bowel, and sexual problems. Active surveillance seeks to preserve those functions while retaining the option of curative treatment if the cancer’s behavior changes.

The rising use of surveillance reflects evidence accumulated over several decades, including research associated with UCSF that helped establish the approach as a national standard for low-risk disease. Long-term studies have found that carefully selected patients managed with surveillance can experience survival outcomes similar to those of patients treated immediately, particularly when the cancer has a very low likelihood of spreading. The comparison is not simply between treatment and no treatment. It is between immediate treatment for everyone and a risk-adapted strategy in which low-risk patients are monitored and higher-risk biological features prompt intervention. This distinction is crucial because the goal is not to avoid treatment at all costs; it is to ensure that treatment is directed toward tumors capable of causing harm.

The new VA data also illuminate how health-system design can influence cancer care. Grace Lee, a UCSF urology resident and physician at the San Francisco VA, said the surveillance approach may be more common in the VA than in outside clinical practices because the system can track quality measures, provide feedback to physicians, and maintain long-term continuity of care. Those features are particularly important for active surveillance, which depends on reliable follow-up rather than a single decision made at diagnosis. A patient must receive scheduled PSA tests, imaging, and biopsies, and clinicians must recognize when results warrant a change in strategy. In a fragmented healthcare environment, missed appointments, incomplete records, or changes in insurance and providers can make that process more difficult. An integrated system can create reminders, standardize protocols, and monitor whether patients remain safely within the surveillance pathway.

The study’s findings also carry a message about the consequences of prostate cancer screening. Screening can save lives by identifying aggressive cancers before they spread, when surgery or radiation may be more effective. Yet the same process can uncover tumors that would never have become clinically important. This phenomenon, known as overdiagnosis, occurs when a screening program detects a disease that would not have caused symptoms or death during the patient’s lifetime. Overtreatment follows when that diagnosis is treated as an unavoidable medical emergency. Matthew Cooperberg, senior author of the study and the Helen Diller Family Chair in the UCSF Department of Urology, said screening detects many slow-growing prostate tumors that should rarely require immediate treatment. He noted that some experts increasingly question whether the least dangerous lesions should even be labeled “cancer,” because the word can produce fear and push patients toward unnecessary procedures.

That concern does not mean surveillance is appropriate for every man with prostate cancer. Risk classification incorporates the tumor’s grade, the amount of cancer found in biopsy samples, PSA levels, clinical examination, imaging findings, and other factors. Low-risk disease generally has features associated with limited growth and a low probability of metastasis. Favorable intermediate-risk disease occupies a more complicated middle ground: some tumors in this group can be monitored safely, while others may benefit from treatment depending on the patient’s age, health, tumor volume, genetic features, and preferences. Surveillance also requires psychological readiness. Repeated tests can create anxiety, and a rising PSA does not always mean that cancer has become more aggressive. Inflammation, prostate enlargement, infection, and testing variability can all affect the marker. For that reason, treatment decisions usually depend on a pattern of evidence rather than a single abnormal result.

The researchers’ conclusions are based on observational data from veterans receiving care in the VA system, so the results do not prove that the health system alone caused the increase or that identical rates would occur in every population. Veterans may differ from privately insured patients in age, medical history, access to specialists, and the way their cancers are detected and classified. The study nevertheless provides a powerful snapshot of changing medical practice at national scale. It shows that active surveillance has moved from a pioneering concept to a mainstream response to low-risk prostate cancer, with adoption accelerating as clinical evidence, monitoring technology, and physician experience have matured. The trend may also reflect better conversations between patients and clinicians about the tradeoff between a possible reduction in cancer risk and the immediate harms of treatment.

For men newly diagnosed with low-risk prostate cancer, the central question is increasingly not “How quickly can the tumor be removed?” but “How likely is this tumor to cause harm, and how confidently can we monitor it?” The VA experience suggests that, when surveillance is organized and follow-up is dependable, most men in this category can avoid or postpone invasive treatment without abandoning cancer care. The approach transforms diagnosis into an ongoing assessment of tumor biology. As screening continues to identify more early-stage disease, the ability to distinguish dangerous cancers from indolent ones will become even more important. The dramatic rise from 27% to 93% among veterans indicates that prostate cancer medicine is entering an era in which restraint, precision, and continuous measurement may protect patients as much as immediate intervention.

Subject of Research: Active surveillance for low-risk and favorable intermediate-risk prostate cancer among U.S. veterans.

News Publication Date: August 13.

Web References: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.13471

References: JAMA study by researchers from the University of California, San Francisco; San Francisco VA Health Care System; VA Boston Healthcare System; Harvard Medical School; and Boston University School of Medicine. UCSF researchers Matthew Cooperberg and Grace Lee were quoted in the source material.

Keywords: Prostate cancer, active surveillance, cancer screening, PSA testing, prostate tumors, Veterans Affairs, urology, radiation therapy, prostate surgery, cancer overdiagnosis.

Focal therapy has attracted considerable attention because it occupies a middle ground between active surveillance and whole-gland treatment. Instead of removing the prostate or irradiating the entire organ, physicians use energy or another localized method to target visible or biopsy-confirmed cancer. Depending on the technology, treatment may rely on high-intensity focused ultrasound, cryoablation, laser energy, irreversible electroporation, or other methods that cause tumor-cell death while attempting to preserve surrounding tissue. The intended benefit is to reduce complications such as urinary incontinence and erectile dysfunction, which can follow radical prostatectomy or radiation therapy.

The biological rationale is appealing but technically demanding. Prostate cancer is frequently multifocal, meaning that more than one malignant focus may exist within the gland. Imaging and biopsy can identify clinically significant lesions, but neither method guarantees that every relevant tumor focus has been detected. A focal procedure can therefore eliminate the known target while leaving undiagnosed disease elsewhere in the prostate. This uncertainty is one reason professional guidelines have generally limited the routine use of focal therapy outside carefully selected patients, clinical trials, or structured prospective studies.

The JAMA study used information from the National Cancer Database, a large registry that captures cancer diagnoses and treatment patterns from participating hospitals and cancer centers across the United States. The investigators analyzed patients with nonmetastatic prostate cancer and assessed how often focal therapy was used over time, as well as the risk categories of the patients receiving it. Because the study was retrospective, it did not assign treatments or follow patients under a controlled experimental protocol. Instead, it reconstructed real-world practice from existing medical records and registry data, providing a broad view of adoption but not the same level of evidence as a randomized clinical trial.

Risk classification is central to deciding how prostate cancer should be managed. Low-risk tumors are often slow-growing and may be monitored through active surveillance, while high- and very-high-risk cancers have a greater likelihood of extending beyond the prostate or producing distant metastases. Treatment for more aggressive disease commonly involves combinations of surgery, radiation, and systemic therapy, depending on the tumor’s features and the patient’s overall health. The study’s finding that about half of focal therapy procedures took place in low-, high-, or very-high-risk disease therefore raises different concerns at opposite ends of the spectrum: possible overtreatment in some low-risk patients and possible undertreatment in some aggressive cases.

For men with low-risk prostate cancer, the central clinical question is often whether treatment is needed immediately at all. Active surveillance can avoid or delay treatment-related side effects while physicians monitor prostate-specific antigen levels, imaging findings, and repeat biopsy results. Focal therapy may appear attractive to patients who want an intervention but hope to preserve quality of life. However, destroying a visible lesion does not necessarily eliminate the need for long-term monitoring, and the procedure itself can still produce complications. Without strong comparative evidence, it remains difficult to determine whether focal treatment offers a meaningful advantage over surveillance for most low-risk patients.

The implications are even more complex for high- and very-high-risk tumors. These cancers may contain microscopic disease beyond the treated region, including tumor cells in other parts of the prostate or outside the gland. A localized procedure that targets only one lesion may not address the full biological extent of the disease. The study does not establish that patients receiving focal therapy experienced worse outcomes, because the database analysis was designed to describe patterns of use rather than directly compare survival or cancer recurrence. Nevertheless, the distribution of treatment across risk groups highlights the gap between technological availability and evidence-based selection.

The researchers also observed that overall use of focal therapy remained uncommon. That pattern may reflect several forces operating at once: uncertainty about long-term cancer control, differences in physician training, uneven insurance coverage, limited availability of specialized equipment, and patient preference. It may also indicate that many clinicians continue to reserve focal therapy for selected cases rather than treating it as a standard alternative to surgery or radiation. Temporal trends can reveal whether a new technology is moving from experimental use into routine care, but increasing adoption alone cannot demonstrate that the treatment improves outcomes.

The findings arrive as prostate cancer diagnosis and treatment become increasingly dependent on multiparametric magnetic resonance imaging, targeted biopsy, molecular testing, and sophisticated risk modeling. These tools can improve the identification and characterization of clinically significant tumors, potentially making focal therapy more precise. Yet precision in locating a lesion is not the same as certainty that the lesion represents the entire threat. The essential unanswered questions include which patients are safest to treat, how treatment success should be measured, how often residual or recurrent cancer occurs, and whether focal therapy preserves quality of life without compromising long-term survival.

By documenting how focal therapy is being used across US cancer centers, the study provides a national snapshot of a rapidly evolving area of oncology. Its message is not that focal therapy should never be performed, but that its use requires careful alignment with tumor biology, imaging, biopsy findings, patient priorities, and the strength of available evidence. For patients, the findings underscore the importance of discussing all reasonable options—including active surveillance, surgery, radiation, and clinical trials—with a multidisciplinary care team. For researchers, they reinforce the need for prospective studies with standardized definitions of treatment success, rigorous follow-up, and outcomes that measure both cancer control and quality of life.

Subject of Research: Patterns and temporal trends in the use of focal therapy for nonmetastatic prostate cancer in US cancer centers.

Web References: https://doi.org/10.1001/jama.2026.12411

References: JAMA study based on data from the National Cancer Database; DOI: 10.1001/jama.2026.12411

Keywords: Prostate cancer, focal therapy, active surveillance, cancer treatment, National Cancer Database, oncology, urology, prostate cancer risk, cancer centers, medical imaging

Focal therapy is designed to treat only the portion of the prostate containing clinically significant cancer rather than removing or irradiating the entire gland. Depending on the technology used, clinicians may destroy targeted tissue with heat, freezing, ultrasound energy or other forms of image-guided ablation. The concept is biologically and clinically attractive: by limiting treatment to the tumor-bearing region, physicians hope to preserve more of the surrounding prostate and reduce complications associated with whole-gland surgery or radiation. Those complications can include urinary incontinence, erectile dysfunction and other changes that may substantially affect quality of life. Yet the precision of the procedure depends on accurately identifying the important cancer within the prostate, determining whether disease is truly localized, and ensuring that untreated tissue does not contain clinically meaningful tumor.

The study was led by Quoc-Dien Trinh, M.D., M.B.A., professor and chair of the Department of Urology at the University of Pittsburgh School of Medicine. Researchers used information from the National Cancer Database to examine treatment patterns among 1,179,384 men aged 50 and older who were diagnosed with nonmetastatic prostate cancer between 2010 and 2023. Of those patients, 15,672 received focal therapy. The database provides a broad view of cancer care across the United States, allowing investigators to evaluate how treatment is being used beyond the highly selected populations typically enrolled in clinical trials. When the researchers compared the treated men with contemporary risk-based recommendations, they found that about half fell outside the groups for whom focal therapy is generally supported.

The central issue is the biological diversity of prostate cancer. Risk classification is based on factors such as prostate-specific antigen levels, tumor grade, the extent of cancer in biopsy samples and clinical imaging findings. Men with low-risk disease often have tumors that grow slowly and may never threaten their health. For many of these patients, active surveillance—regular monitoring with blood tests, imaging, repeat biopsies and clinical assessment—can avoid or delay treatment without compromising the opportunity for cure. Focal therapy in this setting may expose a patient to procedural risks and long-term side effects without providing a clear medical advantage over observation. Treating a tumor that is unlikely to progress can turn a condition suitable for monitoring into a source of avoidable harm.

The opposite concern applies to men with high- or very high-risk prostate cancer. These tumors are more likely to extend beyond the original focus, invade surrounding tissue or eventually spread to other parts of the body. Destroying a visible or biopsy-confirmed lesion may not eliminate microscopic cancer elsewhere in the prostate or beyond it. For such patients, surgery, radiation combined with hormone therapy, or other multimodal treatments may offer stronger evidence for durable cancer control. Focal therapy can be highly targeted, but that strength can become a limitation when the disease is biologically aggressive or more extensive than imaging reveals. A treatment that controls one tumor focus may not adequately address the full burden of a high-risk cancer.

For appropriately selected men with intermediate-risk disease, however, the balance can be different. These patients may have cancer significant enough to warrant intervention but localized enough that treatment confined to the dominant tumor could be reasonable. The strategy seeks to preserve healthy tissue while controlling the lesion most likely to determine the cancer’s behavior. Modern imaging, particularly multiparametric magnetic resonance imaging, can help identify suspicious areas and guide targeted biopsies, while advanced navigation systems can assist in planning ablation. Even so, imaging and sampling are imperfect. Prostate cancer may be multifocal, with clinically important disease distributed in separate regions that are difficult to detect or treat through a single targeted procedure.

The researchers stress that their analysis describes treatment patterns rather than proving that every individual procedure was inappropriate. The National Cancer Database does not contain all of the information needed to judge the clinical reasoning behind a treatment decision. It does not fully capture participation in clinical trials or prospective registries, and it lacks detailed long-term outcomes such as cancer recurrence, metastasis, retreatment, side effects, quality of life and treatment cost. A patient outside a guideline-supported category may have received focal therapy as part of carefully monitored research, or because other medical considerations made conventional treatment less desirable. Conversely, a patient who appears to fit an accepted category may still have disease features that make focal therapy unsuitable.

That limitation also highlights a broader challenge in modern medicine: the gap between technological promise and definitive evidence. New procedures can spread quickly when they offer an appealing combination of precision, reduced invasiveness and fewer visible side effects. But a lower short-term burden does not automatically mean equivalent long-term cancer control. Prostate cancer can take many years to recur or progress, making extended follow-up essential. A procedure that preserves sexual or urinary function in the first months after treatment must also be evaluated against the possibility of residual cancer, repeated treatment or delayed recognition of progression. The most meaningful comparisons will require prospective studies that track both oncologic outcomes and the patient’s lived experience over time.

The findings may therefore serve as a warning against treating focal therapy as a universal middle ground between active surveillance and whole-gland treatment. The appropriate choice depends on tumor biology, disease volume, anatomical location, imaging quality, biopsy findings, the expertise of the treatment team and the patient’s priorities. It also requires a clear discussion of uncertainty. Men considering focal therapy should understand that the approach may involve continued surveillance, additional biopsies or retreatment, and that evidence for long-term cancer outcomes remains less mature than it is for established treatments in many risk groups. Shared decision-making is particularly important when the potential benefit is preserving quality of life but the consequences of undertreating a dangerous cancer could be serious.

As focal therapy continues to expand, better patient selection could determine whether the technology fulfills its promise or becomes another example of innovation outpacing evidence. The Pittsburgh team says future research should identify the biological and imaging features that predict successful treatment, clarify which patients require additional therapy, and measure outcomes over long periods. The researchers also caution that procedures performed outside Commission on Cancer-accredited centers may not be represented in the database, meaning the national number of treated patients could be higher than reported. Their overarching message is not that focal therapy has no place in prostate cancer care, but that precision treatment must be matched with precision selection. For each patient, the goal is to choose an intervention that reflects the aggressiveness and distribution of the cancer while protecting quality of life wherever safely possible.

Subject of Research: Focal therapy use and guideline concordance in men with nonmetastatic prostate cancer.

Web References: https://www.urology.pitt.edu/people/quoc-dien-trinh-md-mba ; https://hillman.upmc.com/cancer-care/prostate ; https://www.cdc.gov/prostate-cancer/statistics/index.html

References: JAMA. DOI: 10.1001/jama.2026.12411

Image Credits: UPMC

Keywords: Prostate cancer, focal therapy, active surveillance, cancer treatment, urology, oncology, prostate cancer risk, precision medicine, JAMA, University of Pittsburgh

Prostate cancer is one of the most commonly diagnosed cancers in men, but not every tumor behaves aggressively. Many prostate tumors grow so slowly that they may never cause symptoms or shorten a person’s life, particularly when detected in older adults or in patients with other serious health conditions. Historically, however, a diagnosis could lead quickly to radical prostatectomy, radiation therapy, or other interventions. These treatments can be lifesaving for aggressive disease, but they may also cause long-term complications, including urinary incontinence, erectile dysfunction, bowel problems, and other effects that can significantly alter quality of life. Active surveillance emerged as a way to separate cancers requiring immediate treatment from those that can be safely monitored.

The strategy is not the same as ignoring cancer. Active surveillance generally involves regular testing, including prostate-specific antigen measurements, repeated clinical evaluations, imaging such as magnetic resonance imaging, and, when appropriate, follow-up biopsies. The purpose is to detect biological or pathological signs that a tumor is becoming more dangerous. If evidence of progression appears, treatment can still be offered. Watchful waiting is related but usually less intensive and is often used when the goal is to manage symptoms or overall health rather than to pursue curative treatment. Both approaches reduce the risk that a patient will experience treatment-related harm when the cancer itself poses little immediate danger.

The new study focuses on care delivered throughout the national VA Healthcare System, one of the largest integrated health systems in the United States. Its findings are important because the VA serves a broad veteran population and maintains an extensive clinical infrastructure capable of tracking diagnostic and treatment patterns across many facilities. The reported increase indicates that conservative management is no longer limited to specialized academic centers or individual physicians who have adopted it early. Instead, it has become a much more common part of routine prostate cancer care within the VA, suggesting that system-wide policies, clinical education, improved risk classification, and greater confidence in surveillance may have influenced medical decision-making.

The most striking change occurred among veterans with low-risk prostate cancer. In this group, the proportion managed with active surveillance or watchful waiting rose from just over one in four patients to nearly all patients. A shift from 27% to 93% represents more than a gradual change in clinical preference; it signals a fundamental transformation in the default response to a favorable diagnosis. For many patients, the new approach may mean avoiding surgery or radiation altogether, while retaining the possibility of treatment if their disease later shows evidence of progression. The result could be fewer avoidable complications without sacrificing the opportunity for curative intervention in men whose cancers become more threatening.

The increase was also substantial for favorable intermediate-risk disease, although the final proportion was lower. Use of surveillance or watchful waiting rose from 14% to 61%, meaning that a majority of veterans in this category were managed without immediate definitive treatment. Intermediate-risk disease is more complex because it includes tumors with a greater possibility of progression than low-risk cancers. Some patients may still benefit from treatment at diagnosis, while others may have tumors whose biological behavior remains sufficiently favorable for careful monitoring. The finding that surveillance expanded in this group suggests that clinicians are increasingly incorporating individual tumor characteristics, patient age, life expectancy, preferences, and competing medical conditions into treatment decisions rather than relying on risk labels alone.

The study also highlights why quality matters alongside incidence. Increasing the number of men placed on surveillance is not enough if follow-up is inconsistent or if patients do not receive the testing needed to identify progression. High-quality active surveillance requires reliable systems for scheduling repeat assessments, communicating results, reviewing imaging and pathology, and ensuring that a patient can transition promptly to treatment when necessary. In a large healthcare network, these processes can be difficult to standardize. The researchers’ emphasis on the quality of surveillance indicates that the success of conservative management depends not merely on delaying treatment, but on maintaining an organized clinical safety net around every patient.

Despite the overall improvement, the findings point to continuing disparities in care. The summary of the study indicates that some veterans still do not receive comparable management for favorable-risk prostate cancer, although the available information does not specify which demographic, geographic, socioeconomic, or clinical groups are most affected. Differences may arise from access to urologists, availability of magnetic resonance imaging or confirmatory biopsy, variation among medical centers, health literacy, transportation barriers, or differences in how clinicians and patients understand the risks of surveillance. Addressing such gaps will require more than publishing guidelines. Health systems may need standardized protocols, decision-support tools, patient education, quality audits, and targeted resources for facilities or populations where surveillance is used less consistently or delivered with lower quality.

The results arrive during a broader reassessment of cancer treatment, in which the central question is increasingly not simply whether a tumor can be treated, but whether it needs to be treated immediately. For veterans with favorable-risk prostate cancer, the VA experience suggests that careful monitoring can become the dominant form of care when a health system aligns clinical practice with the biology of the disease. The findings do not mean that surgery and radiation are unnecessary for all prostate cancer patients, nor that surveillance is risk-free. They show instead that a diagnosis can be managed with greater precision, reserving intensive treatment for cancers most likely to benefit from it. By helping many men avoid unnecessary intervention while preserving a pathway to treatment, the VA’s shift may offer a model for improving cancer care beyond the veteran population.

Subject of Research: Prostate cancer management and the use and quality of active surveillance or watchful waiting in the US Department of Veterans Affairs Healthcare System.

Web References: https://doi.org/10.1001/jama.2026.13471

References: Cooperberg MR et al., Research Letter published in JAMA, DOI: 10.1001/jama.2026.13471.

Keywords: Prostate cancer, active surveillance, watchful waiting, Veterans Affairs Healthcare System, low-risk prostate cancer, favorable intermediate-risk prostate cancer, cancer treatment, overtreatment, health disparities.

Prostate cancer remains the most frequently diagnosed cancer among Australian men, yet the earliest molecular events leading to malignant transformation have remained poorly understood. Leveraging cutting-edge technologies including single-cell RNA sequencing and spatial transcriptomics, the research team led by Professor Alexander Swarbrick meticulously analyzed tumor tissue samples from 24 patients recently diagnosed with early localized prostate cancer. This powerful combination of techniques enabled characterization of not only the genetic activity within individual cells but also their precise spatial distribution within the tumor microenvironment, culminating in a comprehensive cellular atlas unprecedented in resolution and scope.

This atlas delineates eleven major cellular classes and more than fifty minor subtypes within prostate cancer tissue, shedding light on the diverse functional states and interactions of epithelial cells, fibroblasts, immune cells, and nervous system components. One of the most striking revelations is the identification of a novel fibroblast subtype, termed perineural cancer-associated fibroblasts (pnCAFs), which congregate around nerve fibers within the tumor mass. The discovery of pnCAFs is particularly significant as perineural invasion—tumor growth along or around nerves—has long been correlated with aggressive prostate cancer and poorer patient outcomes. These fibroblasts exhibit unique gene expression profiles suggestive of specialized communication machinery with peripheral nerves, hinting at an active role in tumor progression or metastasis.

Notably, the study highlights that many epithelial cells often judged histologically ‘normal’ already carry subtle genomic alterations indicative of pre-malignant transformation. Traditional pathology relies on microscopic assessment of cellular morphology to detect cancer, but these findings underscore that genetic changes occur invisibly well before obvious structural aberrations manifest. As such, the study paves the way for developing novel molecular diagnostics capable of identifying nascent cancerous states with higher sensitivity, potentially allowing intervention at an earlier disease stage when therapeutic outcomes are more favorable.

Professor Swarbrick emphasizes the transformative potential of these insights: “Our work presents a molecular narrative of prostate cancer development extending over several years. By revealing that a substantial fraction of supposedly healthy cells harbor early oncogenic mutations, we challenge the sufficiency of existing diagnostic paradigms, advocating for integration of molecular profiling tools into routine clinical workflows.” This paradigm shift aligns with the broader trend in oncology toward precision medicine, where therapies and monitoring are tailored to the patient’s molecular tumor landscape rather than solely morphological criteria.

Clinical implications resonate deeply with Professor Anthony Joshua, who underscores the urgent need for predictive biomarkers to discern which early-stage prostate cancers will progress aggressively. “Although current treatment modalities are effective for most prostate cancer patients, the heterogeneity of the disease mandates more refined stratification strategies. Understanding the sequence of genetic and cellular events that precipitate invasive cancer will empower clinicians to customize surveillance and treatment intensity, sparing low-risk patients from overtreatment while identifying those requiring early, aggressive intervention,” he explains.

The pioneering application of spatial transcriptomics provided a powerful lens to visualize the tumor ecosystem, revealing nuanced intercellular interactions shaping cancer evolution. Mapping gene expression in situ illuminated how fibroblasts, immune cells, and nerve-associated cells are spatially organized and potentially coordinate tumor growth and immune evasion. The close association of pnCAFs with peripheral nerve glial cells suggests complex crosstalk that may facilitate perineural invasion or nerve recruitment into the tumor microenvironment, a recognized hallmark of advanced prostate cancer.

Moving forward, the research team plans to expand their cohort to include a broader spectrum of patients, aiming to validate and refine their atlas while focusing on subpopulations of pre-malignant cells exhibiting cryptic genetic changes. Such efforts will pave the way to fully elucidate the temporal sequence of molecular alterations driving prostate tumorigenesis. Furthermore, mechanistic studies investigating the function of pnCAFs and their interactions with nerves could identify novel therapeutic targets, potentially disrupting perineural invasion pathways known to exacerbate clinical outcomes.

While these findings represent foundational scientific advancements rather than immediate clinical applications, the implications are far-reaching. With prostate cancer imposing significant health burdens globally, introducing molecular early detection assays and therapeutic strategies informed by this comprehensive atlas could revolutionize patient care. Early identification of mutation-harboring but morphologically normal cells would open a therapeutic window to nip cancer development in the bud, ultimately reducing morbidity and mortality associated with this pervasive disease.

This meticulous work was made possible through the Garvan St Vincent’s Prostate Cancer Biobank, the largest collection of prostate cancer tissue samples in the Southern Hemisphere, which has amassed specimens from over 16,000 patients over three decades. The biobank’s extensive repository enabled high-fidelity molecular characterization spanning diverse genetic backgrounds and disease stages, essential for constructing a representative and robust cellular atlas.

In summary, this study marks a significant leap in our understanding of prostate cancer biology by merging state-of-the-art single-cell genomic technologies with spatial tissue mapping. The identification of perineural cancer-associated fibroblasts and the revelation that many ostensibly normal cells carry early cancer-associated genetic changes challenge existing paradigms and open novel research and clinical frontiers. The atlas generated serves as a vital resource for the global scientific community, igniting fresh avenues for early diagnosis, risk assessment, and targeted therapies that could profoundly influence prostate cancer management worldwide.

Subject of Research: People

Article Title: Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy- Naïve Localized Prostate Cancer

News Publication Date: 25-Mar-2026

Web References:
https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-25-1202

References:
Cancer Research, DOI: 10.1158/0008-5472.CAN-25-1202

Image Credits: Garvan Institute

Keywords: Prostate cancer, Cancer, Prostate tumors, Epithelial cells, Single cell sequencing, RNA sequencing

For decades, the medical community has operated under the assumption that elevated testosterone levels promote the growth and aggressiveness of prostate cancer. Testosterone, as a primary androgen hormone, has traditionally been implicated in fueling the proliferation of malignant prostate cells, influencing treatment protocols aimed at lowering androgen levels. However, the new retrospective cohort study published in The Journal of Urology presents a counterintuitive narrative, suggesting that men with low baseline testosterone levels—specifically those measuring 300 ng/dL or below—face a 60% higher likelihood of their prostate cancer advancing to a more aggressive Grade group 3 or higher during active surveillance.

Active surveillance is currently considered a safe and effective management strategy for patients diagnosed with low-risk, localized prostate cancer. It entails close monitoring of the disease, using repeated measurements of prostate-specific antigen (PSA), imaging scans, and targeted biopsies, delaying active treatment interventions unless there is evidence of disease progression. The complexity lies in accurately identifying which patients will maintain indolent disease versus those whose cancer will evolve into a more threatening form. The newly uncovered association between low testosterone and heightened progression risk could become a pivotal piece in this clinical puzzle.

The research team conducted a comprehensive analysis of clinical and pathological data from over 900 men undergoing active surveillance for localized prostate cancer. They meticulously controlled for potential confounding variables, including age, PSA levels, body mass index (BMI), tumor size, and density, to isolate the role of testosterone. The robustness of their findings indicates that testosterone levels at diagnosis might serve as an independent biomarker in predicting disease trajectory. This revelation prompts a reconsideration of hormonal influences in early-stage prostate cancer biology and suggests a more nuanced relationship than previously understood.

Dr. Justin R. Gregg, M.D., associate professor of Urology and Health Disparities Research at MD Anderson and lead author of the study, emphasizes the significance of these findings. He notes that recognizing the hormonal milieu’s impact on cancer progression can enhance personalized surveillance protocols. This could lead to stratifying patients not only based on traditional clinical parameters but by integrating endocrine profiles, creating a more refined and dynamic risk assessment model.

Biologically, the mechanisms underlying why low testosterone correlates with a more aggressive cancer course remain to be fully elucidated. Some hypotheses in the field propose that low androgen environments might select for more dedifferentiated, aggressive cancer clones that are less dependent on hormonal signals, potentially driving disease progression through alternative pathways. This is a stark contrast to the earlier view of testosterone purely as a growth facilitator, illuminating the complexity of endocrine interactions in prostate carcinogenesis.

It is critical to clarify that while this study identifies an association, it does not establish causality. Low testosterone per se is not deemed the cause of aggressive prostate cancer but rather a potential indicator or consequence of tumor biology that predisposes to disease progression. Future prospective studies are necessary to confirm whether baseline testosterone can be reliably used in clinical decision-making frameworks, guiding timing and frequency of surveillance biopsies and imaging, and determining when to transition to definitive treatment.

This research also opens questions about the role of testosterone replacement therapy (TRT) in men with prostate cancer or those at risk. Historically contraindicated due to fears of promoting tumor growth, the emerging evidence from this study and others might eventually support revisiting clinical guidelines. Nonetheless, caution remains paramount given the complexities of androgen signaling and prostate cancer pathophysiology.

For patients and clinicians alike, the study reinforces the importance of a comprehensive approach to prostate cancer management. Measuring testosterone at baseline could become standard practice, aiding in identifying men who might benefit from intensified surveillance or earlier intervention. As personalized medicine continues to evolve, integrating hormonal biomarkers with genomic and imaging data could revolutionize prostate cancer care, minimizing overtreatment while safeguarding against missed progression.

In conclusion, this major study from MD Anderson centers a critical spotlight on the relationship between testosterone and prostate cancer behavior during active surveillance. It welcomes a new era of research dedicated to unraveling endocrine factors in cancer progression, which, if confirmed by subsequent investigations, holds the promise of transforming prostate cancer prognostication and therapeutic decision-making. The findings underscore the necessity of embracing a multidimensional view of cancer biology that transcends traditional dogmas and paves the way for informed, patient-centered care.

Subject of Research: The relationship between baseline testosterone levels and prostate cancer progression in patients under active surveillance.

Article Title: Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study

News Publication Date: 24-Feb-2026

Web References:

• The University of Texas MD Anderson Cancer Center
• The Journal of Urology article DOI: 10.1097/JU.0000000000004986

References: Gregg, J. R., et al. (2026). Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study. The Journal of Urology. DOI: 10.1097/JU.0000000000004986

Keywords: Prostate cancer, testosterone, active surveillance, cancer progression, hormone biomarkers, Grade Group progression, endocrine factors, tumor biology, personalized medicine

Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, with its early and accurate detection being vital for optimal treatment outcomes. Traditionally, risk stratification hinges on the Gleason score, derived from prostate biopsy samples. However, biopsy is invasive and fraught with challenges such as sampling errors and procedural complications. Addressing this clinical gap, the research team harnessed the power of automated machine learning (auto-ML), employing a single imaging modality—T2WI—to create a robust, non-invasive diagnostic tool.

The study utilized MLJAR, an automated machine learning platform, to analyze MRI scans from an internal dataset consisting of prostate cancer patients who underwent imaging prior to biopsy, surgery, or other therapies. This cohort included 489 individuals, with 291 diagnosed with prostate cancer and 198 without, ensuring a comprehensive representation of cases. Notably, the datasets used for external validation extended the study’s reach, drawing from another medical center as well as a publicly available challenge dataset, comprising 45 and 68 prostate cancer cases respectively.

A pivotal part of the investigation involved rigorous statistical methods to ascertain the model’s diagnostic accuracy. The Kolmogorov–Smirnov curve assessed the model’s capability to distinguish risk groups, while the receiver operating characteristic (ROC) curves provided detailed insights into sensitivity and specificity through area under the curve (AUC) metrics. The results were nothing short of remarkable, particularly within the internal test cohort, where prostate cancer detection achieved an AUC of 0.99—an indicator of near-perfect discriminatory power.

Beyond detection, the auto-ML model’s ability to non-invasively predict detailed Gleason scores signified a major leap forward. In the internal-testing cohort, the AUC values for various Gleason score subtypes ranged from 0.87 to a flawless 1.0, demonstrating exceptional precision in differentiating tumor grades—critical for personalized treatment planning. The external validation cohorts mirrored these promising outcomes, with slight variations in AUC values but consistently high diagnostic performance, reinforcing the model’s generalizability across clinical settings.

The integration of automated machine learning into prostate cancer imaging workflows holds transformative implications. Unlike traditional radiological assessments that require expert interpretation and often struggle with subjective variability, this approach standardizes and optimizes data analysis. By leveraging T2-weighted images alone, the methodology simplifies imaging protocols, potentially reducing costs and streamlining patient management while maintaining clinical efficacy.

Importantly, the study underscores the capacity to reduce dependence on invasive biopsies, which, despite being the current gold standard, expose patients to infection risks and discomfort. With validated high accuracy in both detection and grading, the auto-ML model could soon serve as an adjunct or preliminary screening tool, expediting clinical decision-making and improving patient outcomes.

This innovation also aligns with broader trends in machine learning applications within medical imaging, where automation and precision increasingly converge. However, the researchers emphasize the necessity for further validation to confirm the model’s performance in diverse populations and clinical environments. Ongoing efforts will likely focus on integrating the auto-ML system seamlessly into routine diagnostic pathways and examining its utility in longitudinal monitoring.

By demonstrating how artificial intelligence can harness readily accessible imaging data to replace invasive procedures, this work epitomizes the future of precision oncology. It paves the way for earlier, more accurate identification and stratification of clinically significant prostate cancers, potentially extending survival rates and quality of life for countless patients worldwide.

The application of such automated workflows may also encourage the development of personalized therapy regimens tailored to individual tumor characteristics quantified non-invasively. As machine learning algorithms evolve with larger datasets and improved interpretability, their role in clinical oncology will only become more pronounced.

Furthermore, the methodological choice of focusing solely on T2WI is critically relevant for real-world clinical deployment since it avoids reliance on multi-parametric imaging sequences that may not be ubiquitously available. This decision enhances the feasibility and scalability of the approach, making it accessible even in resource-constrained healthcare systems.

This multi-center study significantly advances the field by bridging the gap between computational intelligence and clinical oncology. It offers a pragmatic, patient-centered alternative to the conventional biopsy paradigm, thereby heralding a new era where machine learning accurately predicts cancer characteristics from non-invasive imaging alone.

Future research will likely delve into expanding this auto-ML framework to incorporate additional biomarkers and imaging modalities, facilitating comprehensive multi-dimensional cancer profiling. Collaborations between radiologists, oncologists, and data scientists will be instrumental in refining these models and translating them into impactful clinical tools.

In conclusion, the success demonstrated in this study underscores the transformative potential of artificial intelligence in cancer diagnostics. By reliably detecting prostate cancer and pinpointing the Gleason score non-invasively, the technology stands poised to revolutionize early detection and risk stratification, ultimately enhancing patient care while minimizing procedural risks. The medical community keenly awaits broader trials and eventual integration of this automated machine learning platform into everyday clinical practice.

Subject of Research: Automated machine learning for non-invasive prostate cancer detection and Gleason score prediction using T2-weighted MRI.

Article Title: Automated machine learning for prostate cancer detection and Gleason score prediction using T2WI: a diagnostic multi-center study

Article References:
Jin, L., Ma, Z., Gao, F. et al. Automated machine learning for prostate cancer detection and Gleason score prediction using T2WI: a diagnostic multi-center study. BMC Cancer 25, 1483 (2025). https://doi.org/10.1186/s12885-025-14917-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14917-z